Reimportation Revived? Or an Issue about to Expire?
This article was originally published in RPM Report
Executive Summary
Support for reimportation of lower-priced drugs from outside the US has been a rallying point for Democratic critics of the drug industry for almost a decade. But there are signs that some influential Democrats now view it as a distraction from the real target-cutting drug costs here.
You may also be interested in...
Pharma Must "Continue to Take Chances" In Policy World: Merck VP's Parting Advice
A conversation with Merck VP-global public policy Ian Spatz about the challenges and opportunities facing industry amid the changes in Washington.
Running Away from Part D: No Love for New Rx Benefit on Campaign Trail
It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.
Running Away from Part D: No Love for New Rx Benefit on Campaign Trail
It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.